Stay updated with breaking news from Maximum Use Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.
Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)
Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology...